zimberelimab,etrumadenant,domvanalimab
gilead,otsuka,arcus biosciences
['domvana', 'etrumadenant', 'zimberelimab']
the median progression-free survival was
#zimberelimab monotherapy: 5.4 months
#omvanalimab plus zimberelimab: 9.3 months
#etrumadenant, #domvanalimab, zimberelimab triple therapy: 9.9 months #asco2023 #asco23 #medtwitter #oncology #cancerresearch #science
#iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma